Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Clovis CEO Patrick Mahaffy “The comprehensive ARIEL3 results presented for the first time today demonstrate the potential of rucaparib to extend the time during which the disease is controlled ...

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The new indication would also extend Lynparza's lead in prostate cancer over rival PARP inhibitors like Clovis Oncology's Rubraca (rucaparib), GSK's Zejula (niraparib) and Pfizer's Talzenna ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

Patients with advanced pancreatic cancer with BRCA or PALB2 mutations who are sensitive to platinum-based chemotherapy may be candidates for maintenance therapy with rucaparib. News, April 02 ...

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination ...

Cutting-edge clinical research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is being shared this ...

Weak CYP2C19 inhibitors, including cimetidine (Tagamet), felbamate (Felbatol), modafinil (Provigil), and rucaparib (Rubraca); and moderate CYP3A4 inhibitors, including aprepitant (Emend ...